Worldwide Market Reports

Biopharmaceutical Market Growth Powered with Latest Development Scenario and Influencing Trends

Biopharmaceutical Market Update: Exceeding Expectations of Key Players That Shows Promising Future


Seattle, WA -- (SBWIRE) -- 11/14/2019 -- A Biopharmaceutical, also known as a biologic(al) medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy.

Get more info about "Global Biopharmaceutical Market Report" by requesting Sample Copy HERE:

Biopharmaceutical Market Analysis:

The Global Bio-Pharmaceuticals Market accounted for $186,470 million in 2017, and is projected to reach $516,008 million by 2026, registering a CAGR of 13.01% from 2018 to 2026. Biopharmaceuticals are substances that are produced using living organisms, such as microorganisms and animal cells, and have a high-therapeutic value. These large and complex molecular drugs are also known as biologics and biotech drugs.

The global biopharmaceuticals market is driven by various factors, such as increase in elderly population, surge in prevalence of chronic diseases such as cancer and diabetes, and increase in adoption of biopharmaceuticals globally. Furthermore, rise in strategic collaborations among biopharmaceuticals companies is also anticipated to supplement the growth of the biopharmaceuticals industry.

However, high costs associated with drug development and their threat of failure are factors anticipated to restrain the growth of the global biopharmaceuticals market. Conversely, emerging economies, such as India and China, are anticipated to provide lucrative growth opportunities to the key players involved for business expansion in the global biopharmaceuticals market during the forecast period.

The global biopharmaceuticals market is segmented based on type, application, and region. On the basis of type, the market is divided into monoclonal antibody, interferon, insulin, growth and coagulation factor, erythropoietin, vaccine, hormone, and others. By application, it is categorized into oncology, blood disorder, metabolic disease, infectious disease, cardiovascular disease, neurological disease, immunology, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America Middle East and Africa (LAMEA).

The monoclonal antibody segment dominated the global biopharmaceuticals market in 2017, owing to the wide adoption of these drugs to treat chronic diseases, such as cancer. Furthermore, surge in R&D with respect to oncology drug development is also anticipated to boost the biopharmaceuticals market for monoclonal antibodies.

The report provides an extensive competitive analysis and profiles of the key market players, such as Abbott Laboratories, Amgen, Inc., Biogen, Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Ltd., Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S, Pfizer, Inc., and Sanofi. The other players in the value chain (not included in the report) include Bristol Myers Squibb Company, Bayer AG, and Shire plc.

Want to make an inquiry before purchasing this report and also want a discount? Click HERE: